c63f3f74-14fa-4a9e-9925-30b0f5da7dd9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.680
- E2F_TARGETS+0.580
- INTERFERON_GAMMA_RESPONSE+0.580
- ALLOGRAFT_REJECTION+0.550
- G2M_CHECKPOINT+0.490
- MYC_TARGETS_V1+0.430
- IL6_JAK_STAT3_SIGNALING+0.420
- MYC_TARGETS_V2+0.420
- OXIDATIVE_PHOSPHORYLATION+0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.390
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.380
- PANCREAS_BETA_CELLS-0.330
- UV_RESPONSE_DN-0.330
- HEDGEHOG_SIGNALING-0.310
- TGF_BETA_SIGNALING-0.280
- ANGIOGENESIS-0.230
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.220
- PROTEIN_SECRETION-0.220
- MYOGENESIS-0.210
- NOTCH_SIGNALING-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475171 | — | — | 0.896 |
| 2 | 695836ff-c54b-47bf-8a29-5224811afa7e | — | — | 0.887 |
| 3 | TCGA-E2-A1II-01A-11R-A144-07 | — | E | 0.883 |
| 4 | 20100125.TNBC | — | E | 0.877 |
| 5 | TCGA-CV-A6JZ-01A-11R-A31N-07 | — | — | 0.865 |
| 6 | TCGA-AR-A0U0-01A-11R-A109-07 | — | E | 0.858 |
| 7 | TCGA-BH-A209-01A-11R-A157-07 | — | D | 0.858 |
| 8 | 301853fd-348d-4a99-9625-7da725023c1d | — | — | 0.852 |
| 9 | e8381a92.5379.4ece.8414.230d0f0026e1 | — | cohortA1 | 0.850 |
| 10 | TCGA-UF-A7JO-01A-11R-A34R-07 | — | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.680 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.390 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |